Gpcr & Kinase Targets (2011) Pp


Published on

This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.

Published in: Business, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Gpcr & Kinase Targets (2011) Pp

  1. 1. GPCR & Kinase Targets Advances in drug development from molecular to clinical 13th – 15th April 2011, London, UK BOOK NOW! Key Speakers Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer Guido Zaman, Senior Director GPCR and Kinases, Molecular Pharmacology Unit, Merck Sharp & Dohme Ulrich Wendt, Director, Structural Biology,Sanofi-Aventis Paul Bamborough, Section Head, Computational and Structural Chemistry, GlaxoSmithKline Magalie Rocheville, Investigator, GlaxoSmithKline Will Spooren, Project Leader, Drug Discovery, F. Hoffmann La Roche Alexandre Trifilieff, Senior Investigator, Novartis Leo Widler, Senior Investigator, Novartis Lee Dawson, Director, Biopharmacology, Neurosciences Product Creation Unit, Eisai Benny Bang-Andersen, Chief Scientist & Group Leader, Discovery Chemistry & DMPK, Lundbeck Trevor Howe, Research Fellow, Head of Biophysics & Structural Biology, Janssen Pharmaceutica Stefan Knapp, Principal Investigator, Oxford University Structural Genomics Consortium Luda Diatchenko, Chief Scientific Officer, Algynomics Scott DeWire, Senior Research Scientist & Co-Founder, Trevena Pre-conference Workshop, Wednesday 13th April, 2011 Cell-based assays for GPCR and kinase monitoring Led by: Julian Burke, Chief Scientific Officer, Genetix Driving the Industry Forward | Organised ByMedia Partners To Book Call: +44 (0) 20 7336 6100 |
  2. 2. Conference Introduction GPCR & Kinase Targets 13th – 15th April 2011, London, UK Media Partners:Dear Colleague, is the leading industry-sponsored portal omprising more than 60% of all therapeutic targets, G-protein coupled C for the pharmaceutical sector. Supported by most of the receptor and kinase targets are arguably the most exciting proteins in leading pharmaceutical corporations, provides dynamic pharmacology today. Drugs acting via GPCRs alone have netted over $50bn real-time news, features, events listings and international jobs to industry in sales worldwide, for conditions ranging from diabetes, to hypertension professionals across Europe and the US. and pain. Yet, despite massive investment spanning decades, translating For further information please email: early research to clinical success remains frustratingly slow. New approaches are needed that acknowledge and integrate structural, functional and BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY systems components, to accelerate time-to-market. WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech By attending Visiongain’s GPCR and Kinase Targets conference, you and pharma information and market to make it universally accessible and will engage with leading decision makers and thought leaders, useful for scientific and business processes. Its first step to fulfilling that enabling you to: mission was building the BIOTECHNOLOGY EUROPE platform that will • mprove the efficacy of assays to enhance 7 transmembrane and kinase I allow a quick spread of information in different channels. BIOTECHNOLOGY drug discovery EUROPE offers companies completed internet public relations, publication • ncorporate improved computational models to evaluate drug-receptor I and marketing solutions. One of the mains goals of BIOTECHNOLOGY interactions and allosteric modulation of downstream signalling pathways EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. • valuate gene splicing for μ-opiod drug development E For further information please visit: • arget chemogenomic, Wnt and aneuploid-specific pathways for cancer T Future Pharmaceuticals has forged powerful relationships Driving the Industry Forward | therapy with key industry leaders to provide a platform for • mploy more accurate siRNA screens to map signalling networks E successful brand recognition, and for senior decision-makers to have the • issect variability in chemotherapy through systems pharmacology D means to procure and plan implementation strategies based on the topics • tilise developments in HTS technology to improve patient stratification U covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals • mploy alternatives to mass spectrometry when undertaking research E magazine is geared to create a deep penetration into a highly targeted and • ntegrate cell-signalling and systems biology insights into treatments for I responsive audience, bridging the gap between the industries’ top issues and complex diseases the solutions top-tier vendors can provide. • electively activate and quantify beta-arrestin biased ligands for analgesia S For further information please visit: and heart disease InPharm is the online platform for exclusive • etter modulate parathyroid hormone release to treat osteoporosis B pharmaceutical news, comment, contracts, services, jobs and events and is home to, Pharmafile and Pharmafocus. • ssess pharmacotherapies in clinical development for pulmonary, A neurodevelopmental and antipsychotic diseases For further information please visit: I look forward to meeting you at the conference Best regards John Shah Sponsorship and exhibition opportunities Conference Producer This event offers a unique opportunity to meet and do business with some of the key players in the pharmaceutical and biotech industries. If you have a Who should attend? service or product to promote, you can do so at this event by: Presidents, Chief Executive Officers, VPs, Global Heads, ChiefScientific Officers, Directors, Principal Scientists, Franchise Heads and • Hosting a networking drinks reception Investigators in:• GPCR/Kinase Research • Taking an exhibition space at the conference • Molecular Pharmacology and Bioanalytical Development• Cellular Assays • Advertising in the delegate documentation pack • High-Throughput/High-Content Screening Operations• Compound Profiling • Providing branded bags, pens, gifts, etc.• CNS, Neurodegenerative Disease, Diabetes, Arthritis, Pain, Oncology• Lead Optimisation/Generation If you would like more information on the range of sponsorship or exhibition • In Vitro Sciences• Pre-clinical Development• Medicinal Chemistry possibilities for visiongains GPCR & Kinase Targets Conference, please • Computational Chemistry and Bioapplications• Genomics contact us:• Proteomics• Bioinformatics Ronald Magali, +44 (0)20 7549 9934• Systems Biology• Pharmacovigilance and Safety Testing• Personalised Medicine
  3. 3. Pre-Conference Interactive Workshop GPCR & Kinase Targets Wednesday 13th April 2011 Cell-based assays for GPCR and kinase monitoringLed by: Julian Burke Timings: 9:30 - 10:00 Coffee & Registration 0 Chief Scientific Officer 10:00 - 15:00 Workshop Genetix T iming includes lunch and refreshment breaksAbout the workshop: About your workshop leader: Dr Julian F. Burke Ph.DThe workshop will address issues surrounding cell-based Dr Julian F. Burke Ph.D. is Chief Scientific Officer at Genetix Limited andGPCR and kinase screening. These will include the use of a visiting Professor at the University of Southampton. He has previouslyfluorescent protein reporters as read outs for activation, as held scientific and faculty positions at the University of Sussex wherewell as label free techniques that can be used to monitor he also founded a university spin out company. He has worked for the Medical Research Council, Cancer Research UK and the Roswell Parkand determine pathways of activation. A particular Cancer Centre, New York, USA. He obtained his Ph.D. in Biochemistryfocus will be on the use of primary and iPS stem cells for from the University of Aberdeen, has authored three books onscreening purposes and how these cells reflect current molecular biology and has over 80 publications in refereed journals. He serves on several government funding committees.models of pharmaceutical drug screening. About the companyAbout visiongain: Genetix Limited, now part of Leica Microssytems, currently employsVisiongain is a specialist business information company focused on providingcutting edge products and services across the Pharmaceutical/Biotech, 170 people and has been run as a consistently profitable businessTelecommunications, Defence and Finance sectors, which include reports, developing reagents and instrumentation for the Biopharmaceuticalconferences, online daily news and offline news analysis and bespoke consultancy. industry. The company played a major role in the Human GenomeWith a commitment to innovation and excellence, visiongain offers flexiblesolutions to meet our clients’ business intelligence needs, providing the right project supplying colony pickers to the major academic sequencinginformation at the right time to facilitate the commercial decision-making centres and commercial sequencing companies. The company has nowprocess. Our pharmaceutical products include Pharma Business Daily, the leading evolved and focuses on its core strengths of imaging and analysis indaily email newsletter for the pharmaceutical, biotech and healthcare industries,and a range of independent, high-quality, in-depth reports covering focused and the field of cell biology. Genetix Limited develops systems for earlytopical areas of concern. Our pharmaceutical conferences address the hottest stage therapeutic antibody production, cell screening and cell basedcommercial, regulatory and technical topics and provide an ideal forum for diagnostics.debate and networking for pharmaceutical professionals from around the world.For further information, please visit:
  4. 4. Day 1 GPCR & Kinase Targets Thursday 14th April 201109:00 Registration and refreshments 14:00 A novel alternatively spliced isoform of the mu-opioid receptor (MOR): functional antagonism09:30 Opening address from the Chair • 7TM and 6TM MOR isoforms stimulate counteracting signalling pathways Trevor Howe • Higher 6TM isoforms are linked to hyperalgesia/poor morphine response Research Fellow, Head of Biophysics & Structural Biology Janssen Pharmaceutica • There is clinical potential for developing selective 7TM/6TM compounds Luda Diatchenko09:40 Enabling structure-based drug discovery for GPCR Chief Scientific Officer Algynomics targets using conformationally thermostabilised receptors (StaRs) 14:40 Targeting signalling networks • StaRs enable production of functionally-relevant purified GPCRs • Strategies for selective inhibitor design • acilitates fragment screening by SPR and NMR to find high-quality hits F • Targeting kinases outside the active site • Crystal structures of GPCRs support structure-based drug design • Targeting complex cellular systems Chris Langmead Head of Pharmacology Stefan Knapp Heptares Therapeutics Principal Investigator Oxford University Structural Genomics Consortium10:20 Drug design for G-protein coupled receptors by a ligand based NMR method 15:20 Afternoon refreshments • Development of ligand based NMR methods as a basis for drug design 15:40 Presentation to be announced • Application to protein kinase and GPCR targets Jürgen Moll • Future perspectives for NMR in pharmaceutical research Director, Cell Biology Department Nerviano Medical Sciences Ulrich Wendt Director, Structural Biology Sanofi-Aventis 16:20 Panel discussion: Modelling the interactome11:00 Morning refreshments T opics covered will include ligand efficacy and quantitative and directional protein interaction networks. Functional redundancy and the limitations of 11:20 Selecting and optimising screening assays for single target approaches for complex diseases will be critiqued, in addition to methodological approaches. Please email your questions for the panel 7-transmembrane receptor signalling to: • Label-free assays Chair: Maria Flocco • The importance of primary cells Senior Director, Lead Discovery and Structural Biology & Biophysics Pfizer • A holistic approach to cell signalling Magalie Rocheville Magalie Rocheville Investigator Investigator GlaxoSmithKline GlaxoSmithKline Stefan Knapp Principal Investigator, Structural Genomics Consortium 12:00 Chemogenomic analysis of protein kinases in University of Oxford Wnt/Frizzled signalling • Importance of abnormal Wnt/ β-catenin in disease • Development of a fast, reliable assay to measure intracellular signalling 17:00 Closing remarks from the chair • Clinical applications Guido Zaman Senior Director GPCR and Kinases, Molecular Pharmacology Unit 17:10 Networking drinks Merck Sharp & Dohme Take your discussions further and build new relationships in a relaxed and informal setting12:40 Networking lunch Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
  5. 5. Day 2 GPCR & Kinase Targets Friday 15th April 201109:00 Registration and refreshments 12:40 Networking lunch09:30 Opening address from the Chair 13:40 Bioactive peptides and orphan neuropeptides Mark Bunnage on known and orphan GPCRS using beta Executive Director, Medicinal Chemistry arrestin technology Pfizer • Multiple reporter assays • Multiplex Tag-lite assays 09:40 GPCR biased ligand drug discovery: dissecting receptor signaling pathways for better medicines • New internalisation assay based on FRET • GPCRs signal through multiple, independent, intracellular pathways Xavier Leroy Project Leader and Senior Lab Head, Drug Discovery • These signaling pathways can be selectively targeted by biased ligands Actelion Pharmaceuticals • Biased ligands elicit unique pharmacology targeting unmet medical needs Scott DeWire 14:20 Therapeutic utility of neurokinin receptor Senior Research Scientist, Co-founder antagonists in the treatment of schizophrenia Trevena • Rationale for developing NK3 receptor antagonists for schizophrenia • Preclinical evaluation of a number of molecules targeted at this receptor 10:20 Calcium-sensing receptor antagonists: a therapy for established osteoporosis? • linical evaluation and potential utility of other neurokinin modulators C • Secretion of PTH is controlled by CaSRs Lee Dawson Director, Biopharmacology, Neurosciences Product Creation Unit • Clinical benefits in mild-to-moderate osteoporosis Eisai • Prospects for the future Leo Widler 15:00 Afternoon refreshments Senior Investigator Novartis 15:20 Drug targets in autism and neurodevelopmental disorders11:00 Morning refreshments Will Spooren Project Leader, Drug Discovery 11:20 Discovery of PF-610,355, an inhaled once-daily F. Hoffmann La Roche beta-2 adrenoceptor agonist for treatment of asthma & COPD 16:00 Kinase drug discovery for chronic diseases, and • otent, inhaled long-acting β2 agonist for treatment of P the discovery of Losmapimod respiratory disease • Selectivity in kinase system-based drug discovery • Long in vivo duration supporting once-daily dosing in humans • Case study: Losmapimod, a p38 kinase inhibitor • Clinical POC achieved and compound in advanced phase II studies Paul Bamborough Section Head, Computational and Structural Chemistry Mark Bunnage GlaxoSmithKline Executive Director, Medicinal Chemistry Pfizer 16:40 Chair’s closing remarks12:00 Toward an understanding of the observed clinical profile for Indacaterol, the first once-daily inhaled 16:50 End of conference beta-2 adrenoceptor agonist • Indacaterol combines fast onset and once daily dosing for COPD • Long lasting action is believed to be due to its lipophilic properties • Its fast onset is linked to its intermediate intrinsic efficacy Alexandre Trifilieff Senior Investigator Novartis
  6. 6. Registration Form GPCR & Kinase Targets 13th – 15th April 2011, London, UK Conf. code Standard PricesConference and workshopConference only Fee: £1699 Fee: £1299 VAT: £339.80 VAT: £259.80 Total: £2038.80 Total: £1558.80 GPCR & Kinase TargetsWorkshop only Fee: £599 VAT: £119.80 Total: £718.80 13th – 15th April 2011Number of bookings: Total cost: London, UKPromotional Literature DistributionDistribution of your company’s promotional literature to all conference attendees Fee: £999 VAT: £199.80 Total: £1198.80Details How to bookForename: Surname: Email: Web: Job Title: Company: UK Office: Tel: +44(0) 20 7336 6100Main Switchboard Number: Fax: +44(0) 20 7549 9932 Visiongain LtdAddress: BSG House 226-236 City Road London EC1V 2QY UKCountry: Postcode: General informationPhone: Fax: Venue: TBA, London, UK Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may Email: be requested if payment has not been received in full before the event. Visiongain Ltd reserves the right to charge interest on unpaid invoices.Signature: Substitutions/name changes or cancellations: There is a 50% liability on all bookings once made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or I confirm that I have read and agree to the terms and conditions of booking after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places Methods of payment between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and Payment must be made in sterling substitutions must be from the same company or organisation and are not transferable between countries. Please note that discounted delegates places at a visiongain event are non refundable.By Mail: Complete and return your signed registration form together with your cheque payable Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK excluding substitutions/name changes, requested by the customer. This will be charged to the customer by credit card prior to the changes being made.By Fax: Complete and fax your signed registration form with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the By Bank Transfer: cost of the registration, travel and expenses. Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data Visiongain Ltd A/C: visiongain Ltd Protection Act 1988. Your personal information contained in this form may be used to update you on Barclays Bank Sort Code: 20-71-64 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you Piccadilly Branch Account No: 6038 7118 wish for your details to be amended, suppressed or not passed on to any external third party, please 48 Regent Street Swift Code: BARC GB22 send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY. Alternatively, you can visit our website at and amend your details. London, W1B 5RA IBAN: GB80 BARC 20716460387118 Please allow approximately 30 days for your removal or update request to be applied to our database. Please debit my credit card: Following your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes are coming into effect. Access MasterCard Visa American Express Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly recommend you obtain).Card number: VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, Eurocash specialise in recovering cross-border VAT.Expiry Date: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.Security number (last 3 digits on back of credit card): Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send Signature: with your payment. You will receive speaker talks in PDFs two weeks after the event. Yes, please send me speaker talks Price£550 VAT:£110 Total:£660Cardholder’s name: Office use onlyNews updatesPlease tick if you do not want to receive email news updates in the future